CAS No.: 283173-55-1
Molecular Formula: C20H21ClO4 | Molecular Weight: 360.84
Dosage Form: Tablet (0.1mg, 0.2mg) | Manufacturer: Kowa Pharmaceutical
Product Overview
Pemafibrate is a novel selective peroxisome proliferator-activated receptor α (PPARα) modulator, mainly used for the treatment of dyslipidemia, with high selectivity and good safety.
Mechanism of Action
• Selectively activates PPARα, regulating lipid metabolism to reduce triglycerides (TG) and increase high-density lipoprotein cholesterol (HDL-C).
• Low affinity for PPARγ/δ, minimizing adverse reactions related to non-selective PPAR agonists.
Indications
Approved: Hypertriglyceridemia, mixed dyslipidemia, especially for patients with high TG and low HDL-C.
Key Advantages
• High PPARα selectivity | • Oral administration, convenient dosage | • Low risk of myopathy and hepatotoxicity | • Effective lipid regulation
China [CN] 
Click enlarge Image